心血管疾病的药物基因组学。
Pharmacogenomics in Cardiovascular Diseases.
机构信息
Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida.
出版信息
Curr Protoc. 2021 Jul;1(7):e189. doi: 10.1002/cpz1.189.
Abstract
Cardiovascular pharmacogenomics is the study and identification of genomic markers that are associated with variability in cardiovascular drug response, cardiovascular drug-related outcomes, or cardiovascular drug-related adverse events. This overview presents an introduction and historical background to cardiovascular pharmacogenomics, and a protocol for designing a cardiovascular pharmacogenomics study. Important considerations are also included for constructing a cardiovascular pharmacogenomics phenotype, designing the replication or validation strategy, common statistical approaches, and how to put the results in context with the cardiovascular drug or cardiovascular disease under investigation. © 2021 Wiley Periodicals LLC. Basic Protocol: Designing a cardiovascular pharmacogenomics study.
摘要
心血管药物基因组学是研究和鉴定与心血管药物反应、心血管药物相关结局或心血管药物相关不良事件的变异性相关的基因组标记物。本综述介绍了心血管药物基因组学的介绍和历史背景，以及设计心血管药物基因组学研究的方案。还包括构建心血管药物基因组学表型、设计复制或验证策略、常见的统计方法以及如何将结果与正在研究的心血管药物或心血管疾病联系起来的重要考虑因素。© 2021 Wiley Periodicals LLC. 基本方案：设计心血管药物基因组学研究。
相似文献
1
Pharmacogenomics in Cardiovascular Diseases.心血管疾病的药物基因组学。
Curr Protoc. 2021 Jul;1(7):e189. doi: 10.1002/cpz1.189.
2
Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner.临床医生的心血管药物动力学、药效学和药物基因组学
J Cardiovasc Pharmacol Ther. 2016 Jan;21(1):20-6. doi: 10.1177/1074248415590196. Epub 2015 Jun 8.
3
Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.心血管疾病中的药物基因组学挑战：药物实例及未来整合至临床实践的考量
Curr Pharm Biotechnol. 2017;18(3):231-241. doi: 10.2174/1389201018666170123153626.
4
Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.药物基因组学在老年心血管疾病治疗患者中的应用。
Croat Med J. 2020 Apr 30;61(2):147-158. doi: 10.3325/cmj.2020.61.147.
5
Cardiovascular pharmacogenomics.心血管药物基因组学。
Circ Res. 2011 Sep 16;109(7):807-20. doi: 10.1161/CIRCRESAHA.110.230995.
6
Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.药物遗传学、药物基因组学与心血管治疗学：前进之路。
Am J Cardiovasc Drugs. 2002;2(5):287-96. doi: 10.2165/00129784-200202050-00001.
7
Cardiovascular pharmacogenomics and individualized drug therapy.心血管药物基因组学与个体化药物治疗
Nat Rev Cardiol. 2009 Oct;6(10):632-8. doi: 10.1038/nrcardio.2009.154. Epub 2009 Aug 25.
8
Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study.为精准医学生成证据：当设计和实施 PREPARE 研究时，无处不在的药物基因组学联盟所考虑的因素。
Pharmacogenet Genomics. 2020 Aug;30(6):131-144. doi: 10.1097/FPC.0000000000000405.
9
Cardiovascular Pharmacogenomics--Implications for Patients With CKD.心血管药物基因组学——对慢性肾脏病患者的影响
Adv Chronic Kidney Dis. 2016 Mar;23(2):82-90. doi: 10.1053/j.ackd.2015.12.001.
10
Cardiovascular drugs and the genetic response.心血管药物与基因反应。
Methodist Debakey Cardiovasc J. 2014 Jan-Mar;10(1):13-7. doi: 10.14797/mdcj-10-1-13.
引用本文的文献
1
Exploring the Role of Genetic and Genomic Factors in Therapeutic Response to Heart Failure: A Comprehensive Analytical Review.探索遗传和基因组因素在心力衰竭治疗反应中的作用：一项综合分析综述。
Genes (Basel). 2025 Jul 4;16(7):801. doi: 10.3390/genes16070801.
2
Pharmacogenomics revolutionizing cardiovascular therapeutics: A narrative review.药物基因组学对心血管治疗的变革：一篇综述
Health Sci Rep. 2024 Oct 20;7(10):e70139. doi: 10.1002/hsr2.70139. eCollection 2024 Oct.
3
Omics Science and Social Aspects in Detecting Biomarkers for Diagnosis, Risk Prediction, and Outcomes of Carotid Stenosis.检测颈动脉狭窄诊断、风险预测和结果的生物标志物的组学科学与社会方面。
Biomolecules. 2024 Aug 8;14(8):972. doi: 10.3390/biom14080972.
4
Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review.人工智能引领心血管照护变革：从发现到实践：JACC 前沿观点述评。
J Am Coll Cardiol. 2024 Jul 2;84(1):97-114. doi: 10.1016/j.jacc.2024.05.003.
5
Review on Emerging Therapeutic Strategies for Managing Cardiovascular Disease.新兴治疗策略在心血管疾病管理中的应用综述
Curr Cardiol Rev. 2024;20(4):e160424228949. doi: 10.2174/011573403X299265240405080030.
6
Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare.推进精准医学：药物研发、临床药理学和个性化医疗中创新的计算机模拟方法综述。
Pharmaceutics. 2024 Feb 27;16(3):332. doi: 10.3390/pharmaceutics16030332.
7
Insight into Risk Factors, Pharmacogenetics/Genomics, and Management of Adverse Drug Reactions in Elderly: A Narrative Review.老年人药物不良反应的风险因素、药物遗传学/基因组学及管理的深入探讨：一项叙述性综述
Pharmaceuticals (Basel). 2023 Nov 1;16(11):1542. doi: 10.3390/ph16111542.
8
Pharmacogenomics in clinical trials: an overview.临床试验中的药物基因组学：概述
Front Pharmacol. 2023 Oct 20;14:1247088. doi: 10.3389/fphar.2023.1247088. eCollection 2023.
9
CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt.埃及经皮冠状动脉介入治疗后服用氯吡格雷的缺血性心脏病患者 CYP2C19 多态性。
J Epidemiol Glob Health. 2023 Jun;13(2):374-383. doi: 10.1007/s44197-023-00113-4. Epub 2023 May 18.
10
Drug-Drug-Gene Interactions in Cardiovascular Medicine.心血管医学中的药物-药物-基因相互作用
Pharmgenomics Pers Med. 2022 Nov 2;15:879-911. doi: 10.2147/PGPM.S338601. eCollection 2022.
本文引用的文献
1
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.基因指导的口服 P2Y12 抑制剂选择与常规氯吡格雷治疗对经皮冠状动脉介入治疗后缺血结局的影响：TAILOR-PCI 随机临床试验。
JAMA. 2020 Aug 25;324(8):761-771. doi: 10.1001/jama.2020.12443.
2
Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.遗传因素对黑种人非洲裔患者华法林剂量的影响：系统评价和荟萃分析。
Clin Pharmacol Ther. 2020 Jun;107(6):1420-1433. doi: 10.1002/cpt.1755. Epub 2020 Jan 28.
3
A Genotype-Guided Strategy for Oral P2Y Inhibitors in Primary PCI.一种基于基因型的急性 ST 段抬高型心肌梗死直接经皮冠状动脉介入治疗中口服 P2Y12 抑制剂的策略。
N Engl J Med. 2019 Oct 24;381(17):1621-1631. doi: 10.1056/NEJMoa1907096. Epub 2019 Sep 3.
4
Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies).全基因组范围内对β受体阻滞剂降压反应的荟萃分析：来自 ICAPS（国际抗高血压药物基因组学研究联合会）的结果。
J Am Heart Assoc. 2019 Aug 20;8(16):e013115. doi: 10.1161/JAHA.119.013115. Epub 2019 Aug 19.
5
A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty.经皮冠状动脉介入治疗后基于基因型指导的抗血小板治疗降阶梯方案
Future Cardiol. 2019 Jul;15(4):251-254. doi: 10.2217/fca-2019-0017. Epub 2019 Aug 6.
6
Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.在真实临床环境中，基于 CYP2C19 基因型指导的抗血小板治疗升阶和降阶的频率和临床结局。
Genet Med. 2020 Jan;22(1):160-169. doi: 10.1038/s41436-019-0611-1. Epub 2019 Jul 18.
7
De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis.替格瑞洛转换为氯吡格雷在急性冠脉综合征患者中的应用：系统评价和荟萃分析。
J Thromb Thrombolysis. 2019 Jul;48(1):1-10. doi: 10.1007/s11239-019-01860-7.
8
Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.心血管药物基因组学的机遇与挑战：从发现到实施。
Circ Res. 2018 Apr 27;122(9):1176-1190. doi: 10.1161/CIRCRESAHA.117.310965.
9
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).PEAR 研究（抗高血压反应的药物基因组学评估）中影响高血压患者血浆肾素活性的遗传变异。
Circ Genom Precis Med. 2018 Apr;11(4):e001854. doi: 10.1161/CIRCGEN.117.001854.
10
Direct oral anticoagulants versus warfarin: is new always better than the old?直接口服抗凝剂与华法林：新的就一定比旧的好吗？
Open Heart. 2018 Feb 7;5(1):e000712. doi: 10.1136/openhrt-2017-000712. eCollection 2018.
Zotero 插件